Kalle E Mattila
Overview
Explore the profile of Kalle E Mattila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattila K, Tiainen L, Vikkula J, Kreutzman A, Engstrom-Risku M, Kysenius K, et al.
Future Oncol
. 2024 Sep;
20(40):3491-3505.
PMID: 39345100
First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT). Retrospective...
2.
Virtanen S, Pihlman H, Silvoniemi M, Vihinen P, Jaakkola P, Mattila K
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398099
Immune checkpoint inhibitors (ICI) have improved survival in several cancer types. Still, most patients develop disease progression during or after treatment. We evaluated the reasons for treatment discontinuation and their...
3.
Mattila K, Vihinen H, Heerva E, Nuotio M, Vihinen P
J Geriatr Oncol
. 2024 Jan;
15(2):101701.
PMID: 38219332
Introduction: Despite being diagnosed with thicker and more often ulcerated melanomas, cancer-specific survival (CSS) is not necessarily inferior in older adults with melanoma compared to younger patients. Materials And Methods:...
4.
Holsa O, Teittinen K, Anttalainen A, Ukkola-Vuoti L, Summanen M, Mattila K
Ther Adv Urol
. 2023 Nov;
15:17562872231206243.
PMID: 37941979
Background: Novel receptor tyrosine kinase inhibitors and immune checkpoint inhibitors have been introduced to the treatment of advanced renal cell carcinoma (aRCC) during the past decade. However, the adoption of...
5.
Vihinen H, Jokinen A, Laajala T, Wahid N, Peltola L, Kettunen T, et al.
Clin Lung Cancer
. 2023 Feb;
24(4):295-304.
PMID: 36774235
Background: Antibiotic treatment may reduce the efficacy of cancer immunotherapy by disrupting gut microbiome. We aimed to study the association of antibiotics and survival outcomes in advanced cutaneous melanoma and...
6.
Mattila K, Makela S, Kytola S, Andersson E, Vihinen P, Ramadan S, et al.
Acta Oncol
. 2022 Oct;
61(10):1263-1267.
PMID: 36307938
Background: Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients. Material And Methods: We studied plasma ctDNA as a prognostic biomarker in 19 patients with...
7.
Mattila K, Vainio P, Jaakkola P
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008402
Approximately 20% of patients with renal cell carcinoma (RCC) present with primarily metastatic disease and over 30% of patients with localized RCC will develop distant metastases later, after complete resection...
8.
Tulokas S, Kohtamaki L, Makela S, Juteau S, Alback A, Vikatmaa P, et al.
Melanoma Res
. 2021 Jun;
31(5):456-463.
PMID: 34132224
Isolated limb perfusion (ILP) is widely accepted as treatment for recurrent melanoma limited to the limbs. The use of ILP has decreased in recent years with the introduction of potentially...
9.
Mattila K, Laajala T, Tornberg S, Kilpelainen T, Vainio P, Ettala O, et al.
Sci Rep
. 2021 Apr;
11(1):8650.
PMID: 33883645
After surgery of localized renal cell carcinoma, over 20% of the patients will develop distant metastases. Our aim was to develop an easy-to-use prognostic model for predicting metastasis-free survival after...
10.
Mattila K, Vihinen P, Ramadan S, Skytta T, Tiainen L, Vuoristo M, et al.
Acta Oncol
. 2019 Oct;
59(3):310-314.
PMID: 31564175
No abstract available.